The specifics, since they change the answer: TSH · orforglipron.
I would rather over-plan the first cycle and simplify later.
I am prepared to do the work if someone can tell me which work matters.
How do I make this decision on evidence rather than on feel?
The relevant statistical point is that a ninety-five per cent reference interval means one analyte in twenty will read out of range in a healthy person by construction.
A twenty-analyte panel run on a healthy person will produce, on average, one out-of-range result purely from how reference intervals are constructed. That is arithmetic rather than pathology.
Repeat before you react. A single abnormal value has a substantial probability of being within the combined biological and analytical variation of a normal one.
Reference intervals are conventionally the central ninety-five per cent of a reference population, which is the direct cause of the one-in-twenty out-of-range rate on a healthy panel.
The caveat is that a panel is not a diagnosis and interpreting one is a clinician's job, particularly when several values move together.
Keep the full report, not the number. You will need the units and the interval later.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsOn the detail: this is answerable, and the answer is mostly about which tests rather than how many.
A sensible core for this population is a full blood count, renal function with electrolytes, liver enzymes with bilirubin, a fasting lipid panel with apolipoprotein B, HbA1c and thyroid-stimulating hormone.
The underlying point is that haemolysis in the sample raises potassium and several enzymes spuriously. If a result is bizarre, ask whether the sample was flagged before building a theory on it.
Biological variation data are published per analyte and are the basis for the reference change value — the difference between two results that is larger than noise.
Research-use compounds are not approved for human use, and no panel makes that safer.
Decide the action for each result before you order the test.
edited 14 Aug 2026 by otto_brenner — tightened the wording; no substantive change
Answer first: decide what you would do differently for each possible result before you order the panel. Anything that fails that test is a number you will worry about and not act on.
Delta checks — comparing against your own previous value — are far more sensitive than comparing against a population interval, which is the argument for keeping a series rather than a snapshot.
Keep the reports rather than the numbers. Units, reference intervals and methods all vary, and a bare number two years later is not comparable to anything.
Ordering tests you will not act on generates anxiety and incidental findings, both of which have costs.
Same laboratory, same time, same fasting state, or the comparison is not a comparison.
Answering this needs to distinguish screening from monitoring. A screening panel looks for the unexpected; a monitoring panel tracks something you already have a reason to watch.
Timing matters per analyte: cortisol and testosterone are diurnal, triglycerides are postprandial, and creatinine responds to hydration and to recent training. Fixing the conditions removes most of the noise.
Nothing here is medical advice. If something is out of range and you do not know why, that is a consultation rather than a research project.
One out-of-range value on a twenty-analyte panel is expected. Two on a repeat is a finding.
The short version: a small, well-chosen panel with a baseline beats a large one without.
Same laboratory, same method, same time of day, same fasting state. Between-laboratory differences on several common analytes are larger than the changes people are trying to detect.
External quality assurance schemes document between-laboratory differences on common analytes that routinely exceed the size of clinically interesting changes.
Baseline first, then a repeat under identical conditions. Everything else is secondary.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.